Publications by authors named "Trilok Parekh"

21Publications

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

J Clin Oncol 2016 Mar 14;34(8):786-93. Epub 2015 Sep 14.

George D. Demetri, Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA; Margaret von Mehren, Fox Chase Cancer Center; Arthur Staddon, University of Pennsylvania, Philadelphia; Hussein Tawbi, University of Pittsburgh Cancer Institute, Pittsburgh, PA; Robin L. Jones, Seattle Cancer Care Alliance, Seattle, WA; Martee L. Hensley, Memorial Sloan Kettering Cancer Center; Robert G. Maki, Mount Sinai Medical Center, New York, NY; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Mohammed Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; Anthony Elias, University of Colorado Cancer Center, Aurora, CO; Kristen Ganjoo, Stanford Hospital and Clinics, Stanford, CA; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Andrew Dean, St John of God Hospital-Bendat Cancer Centre, Subiaco, Western Australia, Australia; Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, and Trilok V. Parekh, Janssen Research & Development, Raritan, NJ; and Shreyaskumar R. Patel, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.4734
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.4734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070559PMC
March 2016

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.

Cancer Chemother Pharmacol 2015 May 20;75(5):1047-55. Epub 2015 Mar 20.

Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2705-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978949PMC
May 2015

The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.

Appl Physiol Nutr Metab 2014 Jun 23;39(6):693-8. Epub 2014 Jan 23.

a Department of Nutrition, Food and Exercise Sciences, The Florida State University, 412 Sandels Building, 120 Convocation Way, Tallahassee, FL 32360, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1139/apnm-2013-0403DOI Listing
June 2014

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

Gynecol Oncol 2014 Jan 5;132(1):176-80. Epub 2013 Nov 5.

PharmaMar, S.A., Avenida de los Reyes 1, P.I. La Mina Norte, Colmenar Viejo, 28770 (Madrid) Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2013.10.032DOI Listing
January 2014

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.

Med Oncol 2013 Mar 9;30(1):435. Epub 2013 Feb 9.

Gynecological, Head and Neck Cancer Division, Department of Medical Oncology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-012-0435-1DOI Listing
March 2013

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.

Eur J Cancer 2012 Oct 26;48(15):2361-8. Epub 2012 Apr 26.

Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.04.001DOI Listing
October 2012

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.

Cancer Chemother Pharmacol 2011 Nov 18;68(5):1223-31. Epub 2011 Mar 18.

PharmaMar, Colmenar Viejo, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1614-zDOI Listing
November 2011

Transforming growth factor-beta, estrogen, and progesterone converge on the regulation of p27Kip1 in the normal and malignant endometrium.

Cancer Res 2007 Feb;67(3):1007-18

Departments of Pathology and Medicine, NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-0235DOI Listing
February 2007

Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.

Cancer Res 2002 May;62(10):2778-90

Department of Pathology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
May 2002